ROVI Rocks!

Laboratorios Farmacéuticos ROVI announces the full-year results for 2024, a key year for setting the bases for ROVI’s future, focused on increasing our production capacities in the contract manufacturing business and reinforcing the company’s internationalisation with Risperidone ISM®.

In 2024, the company obtained operating revenue of 763.7 million euros; EBITDA of 207.4 million euros; and a net profit of 136.9 million euros.

The contract manufacturing business (CDMO) decreased 18% compared to 2023, dropping to 336.2 million, as a consequence of:

– lower revenue related to the manufacture of the COVID-19 vaccine compared with 2023, when ROVI booked higher revenue related to the production of the “pandemic” COVID-19 vaccine; and – lower revenue related to the activities carried out to prepare the plant for vaccine production under the agreement with Moderna.

Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 28.8 million euros in 2024. Okedi® sales in 2024 doubled those of 2023.

Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) slightly decreased by 1% to 248.7 million euros in 2024, mainly due to lower orders from enoxaparin partners throughout the year.

In December 2024, for the fifth year running, ROVI improved its ESG risk rating awarded by Sustainalytics, achieving a low risk of 16.1, compared to 16.4 the previous year. The Company was placed fifth in the world ESG risk ranking from among the 424 companies evaluated in the pharmaceutical industry.

Financial donation of 250,000 euros for the reconstruction of damaged areas

We are pleased to announce that Laboratorios Farmacéuticos ROVI has made a donation of 250,000 euros to the solidarity account set up by the Generalitat Valenciana for the repair of damage and reconstruction of the areas affected by the DANA of 29th of October.

This contribution is part of the actions that the company carries out in emergency and humanitarian situations through the group’s Donations Committee. In this case, the funds will be used to repair the serious material damage caused in numerous urban and rural areas of the province of Valencia as a result of the intense rainfall and floods.

With this collaboration, we hope to contribute to a speedy recovery of the affected areas and the restoration of normal daily life.

Today, 25 November, is the International Day for the Elimination of Violence against Women.

At ROVI we do not tolerate harassment and we reject any form of violence, physical, sexual, psychological or moral harassment, abuse of authority at work or any other form of harassment or conduct that creates an intimidating or offensive environment for the rights of our employees.

ROVI also has an internal information system (Ethics Channel) which allows for fluid and effective communication with the bodies responsible for ensuring compliance with the company’s Code of Ethics, guaranteeing confidentiality and non-retaliation in the event of any type of harassment, abuse or violence suffered by a ROVI employee.

The City Council of Alcalá de Henares, in collaboration with the Official College of Pharmacists of Madrid (COFM), Laboratorios ROVI and the Foundation “España Salud”, have presented the project “Farmacias Cardioprotectoras”, which will allow a total of 24 pharmacies in this city, located in areas where this type of assistance is not forthcoming, to have a defibrillation equipment at the service of anyone who needs it.

This initiative provides for the installation of defibrillators in selected pharmacies, especially those with extended opening hours and away from other health centres. As health professionals closest to the population, community pharmacists will receive the necessary training to act in time, in order to reverse episodes of sudden death or sudden onset of cardiac arrest. The objective is to create a safety network of cardioprotective pharmacies to guarantee the population quick access to these devices, to reduce the number of deaths associated with cardiorespiratory arrests.

Cardiovascular problems are today the first cause of death in women and the second in men in Spain, accounting for 30% of deaths. Defibrillation has been shown to be an effective treatment that involves delivering a controlled electrical shock to the heart with the defibrillator.

“With this project, the pharmacy network once again demonstrates that it offers solutions to improve the care and health of the population; we want to offer greater peace of mind and tell citizens that we are better prepared to face an emergency, where reaction time is key to saving a life,” said the president of COFM, Manuel Martínez del Peral.

Dear colleagues,

I am writing to announce an important transformation in the management of Laboratorios Farmacéuticos ROVI’s most important asset: its employees. As part of our commitment to the continuous improvement and optimisation of our internal processes, we have decided to implement an important change in our human resource management computer system so that we can become swifter and more agile.

To this end, we are going to adopt the Workday programme, a new tool with which we will unify and simplify the people-related administrative and management tasks at ROVI.

This new platform will allow us to centralise human resource management, furnishing each employee with greater autonomy and self-management capacity. When it has been implemented, you will be able to administer aspects related to your time, salary and professional development more directly, with updated information and easily accessible tools.

Impact on the human resources team

With this new computer system, the human resources team will be freed from various administrative tasks, which will allow them to take on a more strategic role in accompanying our workforce and providing advice on their needs. This change will enable the team to focus on supporting the professional development of each colleague and promoting an inclusive and collaborative work environment.

Next step

As of 1 October, Workday will become our partner for day-to-day procedures and may be accessed from both computers and mobile phones. As you know, we have begun/conducted a round of face-to-face sessions to familiarise our employees with the programme and favour their adaptation to the new system and its functionalities.

We firmly believe that this transformation will represent a significant advance for our organisation, allowing us to improve efficiency, autonomy and collaboration at all levels. From the human resources team, we would like to thank you for your commitment and cooperation in making this project a success and we reiterate that we will continue to work with you to enable ROVI to continue growing.

We have the pleasure of announcing that the Board of Directors of Laboratorios Farmacéuticos ROVI has approved the new Human Rights Policy. In this Policy, the Group, as a member of the United Nations Global Compact, reaffirms its commitment to ensuring that the activities conducted in the course of both its own operations and those of its value chain do not violate human rates or the Fundamental Conventions of the International Labour Organisation.

Respect for human rights is one of the basic pillars of ROVI’s values, as set out in its Code of Ethics, Environmental and Social Sustainability Policy and Corporate Social Responsibility Programme, in accordance with the standard SA8000. This new policy supplements these principles with the goal of generating a positive impact on ROVI’s stakeholders (workers, patients, healthcare professionals, suppliers and society) and ensuring that all the Group’s actions are guided by the strictest ethical standards.

CLICK HERE to see the results video

We highlight in this half of 2024:

In this half-year, special attention should be drawn to the 2.8 percentage point increase in the gross margin when compared with the first half of 2023, rising to 59.4%.

Operating revenue decreased 14%, mainly due to a lower contribution from the CDMO business, sales of which decreased to 118.9 million euros.

Operating revenue generated by the specialty pharmaceutical business increased 1% to 210.5 million euros.

Sales of the heparin division (low-molecular-weight heparins and other heparins) totalled 120.7 million euros in the first half of the year.

Low-molecular-weight heparins decreased 2% to 116.9 million euros in the first half of 2024, mainly due to the drop in enoxaparin sales. However, a greater concentration of orders from partners is expected in the second half of 2024.

Bemiparin sales increased 6%, driven mainly by a higher volume of orders from partners in China, Turkey and Greece.

ROVI expects bemiparin sales to increase by a low-single-digit percentage in 2024 compared with 2023. Risperidone ISM® sales rose 141% in the first half of 2024 versus the same period of 2023, totalling 12.5 million euros.

In 2024, this product has been approved in the United States, Canada and Australia, thus reinforcing ROVI’s internationalisation strategy. Risperidone ISM® is expected to reach potential sales of between 200 and 300 million euros globally in upcoming years. R&D expenses rose 13% to 12.2 million euros. Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at present.

Here you can review the new Training Policy of the ROVI Group, in which are described the processes for identifying needs and planning training activities for the ROVI’s workforce.

You can find it on ROVI’s website and in the Documents section of ROVI Rocks.

We’ll be waiting for you

Get ready for the change

The Investment Accelerator of the Community of Madrid has declared as a strategic project the expansion that Laboratorios ROVI will undertake at its plant in San Sebastián de los Reyes (Madrid), with which it plans to increase its current production capacity, thanks to the commissioning of a new high-speed line with a capacity of 100 million syringes.

The expansion project will involve an investment of around 60 million euros. The group has acquired adjoining land for a total area of 54,715 m2, which will increase production capacity by more than 31.5 percent to a total of 420 million prefilled syringes and 80 million vials by 2027.

To respond to the increase in activity, the group will incorporate new buildings for the expansion of production areas and new lines, a new quality laboratory and office building, and auxiliary storage and maintenance buildings, among others. The project envisages providing the industrial complex with new accesses and improving internal circulation, as well as increasing the number of parking spaces to meet the needs of the current and future workforce.

The various investments to increase the plant’s production capacity between 2023 and 2027 will create 200 new direct skilled jobs.

With this, the ROVI Group is positioned as one of the largest industrial pharmaceutical groups in Spain and among the world leaders in the production of injectables.